Granted Patent
B2
US 12,714,722 · App. 17/441,599 · Granted Aug 25, 2026
Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
View Patent ↗
Loading inventors, assignments & file history…
Assignments (5)
MERGER AND CHANGE OF NAME
Recorded May 18, 2026
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 074681/0643 →
CONFIRMATORY LICENSE
Recorded Dec 13, 2023
From: FRED HUTCHINSON CANCER RESEARCH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065968/0293 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT APPLICATION NUMBER 63/242,906 PREVIOUSLY RECORDED ON REEL 060439 FRAME 0279. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME.
Recorded Nov 4, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 061847/0594 →
MERGER AND CHANGE OF NAME
Recorded Jun 23, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060439/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 22, 2021
From: HOCKENBERY, DAVID M.; PADDISON, PATRICK
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 057566/0672 →
Continuity (2)
Provisional Application
62821821
· Mar 21, 2019
References Cited (127)
US 8106184B2
· Sauve et al.
· 2012
[cited by applicant]
US 8197807B2
· Brenner
· 2012
[cited by applicant]
US 8383086B2
· Brenner
· 2013
[cited by applicant]
US 9302989B2
· Curtin et al.
· 2016
[cited by applicant]
US 9335332B2
· Kumaravel et al.
· 2016
[cited by applicant]
US 9382267B2
· Lee, Jr. et al.
· 2016
[cited by applicant]
US 20060229265A1
· Milburn et al.
· 2006
[cited by applicant]
US 20120122924A1
· Curtin et al.
· 2012
[cited by applicant]
US 20130109643A1
· Riggins et al.
· 2013
[cited by applicant]
US 20130273034A1
· Bair
· 2013
[cited by examiner]
US 20150353538A1
· Willardsen et al.
· 2015
[cited by applicant]
US 20160075682A1
· Genazzani et al.
· 2016
[cited by applicant]
US 20160229835A1
· Burkholder et al.
· 2016
[cited by applicant]
US 20180200275A1
· Lawrence
· 2018
[cited by applicant]
CN 104039762B
· 2011
[cited by applicant]
CN 105579449A
· 2014
[cited by applicant]
EP 2213288A1
· 2010
[cited by applicant]
EP 3152220A1
· 2017
[cited by applicant]
JP 2016532648A
· 2016
[cited by applicant]
WO WO2010002465A2
· 2010
[cited by applicant]
WO WO2010111111A1
· 2010
[cited by applicant]
WO WO2012024478A2
· 2012
[cited by applicant]
WO WO2012031197A1
· 2012
[cited by applicant]
WO WO2012177782A1
· 2012
[cited by applicant]
WO WO2014004884A1
· 2014
[cited by applicant]
WO WO2017162840A1
· 2018
[cited by applicant]
WO WO2018236814A2
· 2018
[cited by applicant]
Dondero (Oncoimmunology; 2016, vol. 5, No. 1, e1064578 (9 pages)).
[cited by examiner]
Tsigelny (Oncotarget, 2016, vol. 7, No. 33, 53074-53101).
[cited by examiner]
Hasmann (Cancer Research, 63, 7436-7442, 2003).
[cited by examiner]
Audrito, et al., “Nicotinaminde Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma,” Journal of the National Cancer Institute, vol. 110, No. 3, 2017, pp. 290-303.
[cited by applicant]
Estoppey, et al., “Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells,” Scientific Reports, vol. 7, No. 42728, 2017, pp. 1-6.
[cited by applicant]
Garavaglia, et al., “The high resolution crystal structure of periplasmic Haemophilus unfluenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metablism,” Biochem. J., vol. 441, 2012, …
[cited by applicant]
Neggers, et al., “Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes,” Nat. Comm., vol. 9, No. 502, 2018, pp. 1-14.
[cited by applicant]
Search Report and Written Opinion Dated Jun. 18, 2020 in International Application No. PCT/US2020/024019, 23 pages.
[cited by applicant]
Pollak, et al., “Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy,” PLoS One, vol. 12, No. 3, 2017, pp. 1-22.
[cited by applicant]
Anders, et al., “HTSeq-a Python framework to work with high-throughput sequencing data,” Bioinformatics, vol. 31, No. 2, 2015, pp. 166-169.
[cited by applicant]
Beauparlant, et al., “Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777,” Anticancer Drugs, vol. 20, No. 5, 2009, pp. 346-354.
[cited by applicant]
Becher, et al., “Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies,” Cancer Res., vol. 66, No. 7, 2006, pp. 3355-3359.
[cited by applicant]
Bogan and Brenner, “Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition,” Annu. Rev. Nutr., vol. 28, 2008, pp. 115-130.
[cited by applicant]
Boyer, et al., “Core transcriptional regulatory circuitry in human embryonic stem cells,” Cell, vol. 122, No. 6, 2005, pp. 947-956.
[cited by applicant]
Brennan, et al., “The somatic genomic landscape of glioblastoma,” Cell, vol. 155, No. 2, 2013, pp. 462-477.
[cited by applicant]
Bressan, et al., “Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells,” Development, vol. 144, No. 4, 2017, pp. 635-648.
[cited by applicant]
Brinkman, et al., “Easy quantitative assessment of genome editing by sequence trace decomposition,” Nucleic. Acids. Res., vol. 42, No. 22, 2014, 8 pages.
[cited by applicant]
Bruzzone, et al., “Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE,” PLoS One., vol. 4, No. 11, 2009, 14 pages.
[cited by applicant]
Butler, et al., “Integrating single-cell transcriptomic data across different conditions, technologies, and species,” Nat. Biotechnol., vol. 36, No. 5, 2018, pp. 411-420.
[cited by applicant]
Chen, et al., “G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment,” Genes Dev., vol. 26, No. 22, 2012, pp. 2499-2511.
[cited by applicant]
Chen, et al., “Homogeneous preparations of 3′-phosphoglycolate-terminated oligodeoxynucleotides from bleomycin-treated DNA as verified by electrospray ionization Fourier transform ion cyclotron resonance mass spectromet…
[cited by applicant]
Chi and Sauve, “Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection,” Curr. Opin. Clin. Nutr. Metab. Care., vol. 16, No. 6, 2013, pp. 657-661.
[cited by applicant]
Dean, et al., “Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays,” J. Biomol. Screen., vol. 19, No. 10, 2014, pp. 1372-1382.
[cited by applicant]
Ding, et al., “Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells,” Cancer Discov., vol. 3, No. 2, pp. 198-211.
[cited by applicant]
Ding, et al., “ZNF131 suppresses centrosome fragmentation in glioblastoma stem-like cells through regulation of HAUS5,” Oncotarget, vol. 8, No. 20, 2017, pp. 48545-48562.
[cited by applicant]
Fletcher, et al., “Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells,” Mol. Metab., vol. 6, No. 8, 2017, pp. 819-832.
[cited by applicant]
Formentini, et al., “ Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo,” Biochem. Pharmacol., vol. 77, No. 10, 2009, pp. 1612-1620.
[cited by applicant]
Franchetti, et al., “Stereoselective synthesis of nicotinamide beta-riboside and nucleoside analogs,” Bioorg. Med. Chem. Lett., vol. 14, No. 18, 2004, pp. 4655-4658.
[cited by applicant]
Galli, et al., “Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,” Cancer Res., vol. 64, No. 19, 2004, pp. 7011-7021.
[cited by applicant]
Gebhardt, et al., “Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1,” J. Cell. Biol., vol. 172, No. 1, 2006, pp. 139-149.
[cited by applicant]
Happold, et al., “Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma,” J. Clin. Oncol., vol. 34, No. 7, 2016, pp. 731-7…
[cited by applicant]
Hemmati, et al., “Cancerous stem cells can arise from pediatric brain tumors,” PNAS, vol. 100, No. 25, 2003, pp. 15178-15183.
[cited by applicant]
Herkert and Eilers, “Transcriptional repression: the dark side of myc,” Genes Cancer, vol. 1, No. 6, 2010, pp. 580-586.
[cited by applicant]
Herold, et al., “Negative regulation of the mammalian UV response by Myc through association with Miz-1,” Mol. Cell, vol. 10, No. 3, 2002, pp. 509-521.
[cited by applicant]
Holen, et al., “The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor,” Invest New Drugs, vol. 26, No. 1, 2008, pp. 45-51.
[cited by applicant]
Hollander, et al., “PTEN loss in the continuum of common cancers, rare syndromes and mouse models,” Nat. Rev. Cancer, vol. 11, No. 4, 2011, pp. 289-301.
[cited by applicant]
Hubert, et al., “Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A,” Genes Dev., vol. 27, No. 9, 2013, pp. 1032-1045.
[cited by applicant]
Hughes, et al., “Single-cell western blotting,” Nat. Methods, vol. 11, No. 7, 2014, pp. 749-755.
[cited by applicant]
Inamdar, et al., “Conversion of phosphoglycolate to phosphate termini on 3' overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1,” J. Biol. Chem., vol. 277, No. 30, 2002, pp. 27162-2716…
[cited by applicant]
Jie, et al., “Activation of transient receptor potential vanilloid 4 induces apoptosis in hippocampus through downregulating PI3K/Akt and upregulating p38 MAPK signaling pathways,” Cell Death Dis., vol. 6, No. 6, 2015, …
[cited by applicant]
Jungnickel, et al., “Phosphoinositide-dependent pathways in mouse sperm are regulated by egg ZP3 and drive the acrosome reaction,” Dev. Biol., vol. 304, No. 1, 2007, pp. 116-126.
[cited by applicant]
Kang, et al., “Single cell-resolution western blotting,” Nat. Protoc., vol. 11, No. 8, 2016, pp. 1508-1530.
[cited by applicant]
Kievit, et al., “Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma,” Nanomedicine, vol. 13, No. 7, pp. 2131-2139.
[cited by applicant]
Lee, et al., “Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines,” Cancer Cell, vol. 9, No. 5, 2006, p…
[cited by applicant]
Leslie and Hertog, “Mutant PTEN in Cancer: Worse Than Nothing,” Cell, vol. 157, No. 3, 2014, pp. 527-529.
[cited by applicant]
Liu, et al., “Synthesis of phosphodiester-type nicotinamide adenine dinucleotide analogs,” Tetrahedron, vol. 65, 2009, pp. 8378-8383.
[cited by applicant]
Metallo, et al., “Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells,” J. Biotechnol., vol. 144, No. 3, 2009, pp. 167-174.
[cited by applicant]
Mugabo, et al., “Identification of a mammalian glycerol-3-phosphate phosphatase: Role in metabolism and signaling in pancreatic ß-cells and hepatocytes,” PNAS, vol. 113, No. 4, 2016, pp. 430-439.
[cited by applicant]
Nikiforov, et al., “Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation,” J. Biol. Chem., vol. 286, No. 24, 2011, pp. 2176…
[cited by applicant]
O'Reilly, et al., “Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours,” Eur. J. Cancer, vol. 29A, No. 7, 1993, pp. 940-942.
[cited by applicant]
Olesen, et al., “A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor,” Mol. Cancer Ther., vol. 9, No. 6, 2…
[cited by applicant]
Olesen, et al., “Anticancer agent CHS-828 inhibits cellular synthesis of NAD,” Biochem. Biophys. Res. Commun., vol. 367, No. 4, 2008, pp. 799-804.
[cited by applicant]
Ostrom, et al., “CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012,” Neuro Oncol., vol. 17, No. 4, 2015, 62 pages.
[cited by applicant]
Ozawa, et al., “Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma,” Cancer Cell, vol. 26, No. 2, 2014, pp. 288-300.
[cited by applicant]
International Report on Preliminary Patentability Dated Sep. 30, 2021 for International Application No. PCT/US2020/024019, 16 pages.
[cited by applicant]
Pollard, et al., “Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens,” Cell Stem Cell, vol. 4, No. 6, 2009, pp. 568-580.
[cited by applicant]
Povirk, Lawrence, “Processing of damaged DNA ends for double-strand break repair in mammalian cells,” ISRN Mol. Biol., vol. 2012, No. 345805, 2012, 16 pages.
[cited by applicant]
Rane, et al., “A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth,” Sci. Rep., vol. 7, No. 42555, 2017, 12 pages.
[cited by applicant]
Ratajczak, et al., “NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells,” Nat. Commun., vol. 7, No. 13103, 2016, 12 pages.
[cited by applicant]
Robinson, “edgeR: a Bioconductor package for differential expression analysis of digital gene expression data,” Bioinformatics, vol. 26, No. 1, 2010, pp. 139-140.
[cited by applicant]
Robinson, et al., “edgeR: a Bioconductor package for differential expression analysis of digital gene expression data,” Bioinformatics, vol. 26, No. 1, 2010, pp. 139-140.
[cited by applicant]
Sampath, et al., “Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer,” Pharmacol Ther., vol. 151, 2015, pp. 16-31.
[cited by applicant]
Sanjana, et al., “Improved vectors and genome-wide libraries for CRISPR screening,” Nat. Methods, vol. 11, No. 8, 2014, pp. 783-784.
[cited by applicant]
Schaniel, et al., “Smarcc1/Baf155 couples self-renewal gene repression with changes in chromatin structure in mouse embryonic stem cells,” Stem Cells, vol. 27, No. 12, 2009, pp. 2979-2791.
[cited by applicant]
Segerer, et al., “An essential developmental function for murine phosphoglycolate phosphatase in safeguarding cell proliferation,” Sci. Rep., vol. 6, No. 35160, 2016, 13 pages.
[cited by applicant]
Seifried, et al., “Reversible oxidation controls the activity and oligomeric state of the mammalian phosphoglycolate phosphatase AUM,” Free Radic Biol Med., vol. 97, 2016, pp. 75-84.
[cited by applicant]
Singh, et al., “Identification of human brain tumour initiating cells,” Nature, vol. 432, No. 7015, 2004, pp. 396-401.
[cited by applicant]
Singh, et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Res., vol. 63, No. 18, 2003, pp. 5821-5828.
[cited by applicant]
Stupp, et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” N. Engl J. Med., vol. 352, No. 10, 2005, pp. 987-996.
[cited by applicant]
Sturm, et al., “New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs,” Cell, vol. 164, No. 5, 2016, pp. 1060-1072.
[cited by applicant]
Szeliga, et al., “Lack of expression of the liver-type glutaminase (LGA) mRNA in human malignant gliomas,” Neurosci Lett., vol. 374, No. 3, 2005, pp. 171-173.
[cited by applicant]
Tanimori, et al., “An efficient chemical synthesis of nicotinamide riboside (NAR) and analogues,” Bioorg. Med. Chem. Lett., vol. 12, No. 8, 2002, pp. 1135-1137.
[cited by applicant]
Tian, et al., “Activation of Transient Receptor Potential Vanilloid 4 Impairs the Dendritic Arborization of Newborn Neurons in the Hippocampal Dentate Gyrus through the AMPK and Akt Signaling Pathways,” Front Mol. Neuro…
[cited by applicant]
Toledo, et al., “Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells,” Cell Rep., vol. 13, No. 11, 2015, pp. 2425-2439.
[cited by applicant]
Trammell and Brenner, “Targeted, LCMS-based Metabolomics for Quantitative Measurement of NAD(+) Metabolites,” Comput. Struct. Biotechnol J., vol. 4, No. 5, 2013, 9 pages.
[cited by applicant]
Trammell, et al., “Nicotinamide riboside is uniquely and orally bioavailable in mice and humans,” Nat. Commun., vol. 7, No. 12948, 2016, 14 pages.
[cited by applicant]
Trapnell, et al., “Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks,” Nat. Protoc., vol. 7, No. 3, 2012, pp. 562-578.
[cited by applicant]
Verhaak, et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1,” Cancer Cell, vol. 17, No. 1, 2010, pp. 98-110.
[cited by applicant]
Von Heideman, et al,, “Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data,” Cancer Chemother Pharmacol, vol. 65, No. 6, 2010, pp. 1165-1172.
[cited by applicant]
Wang, et al., “Allele-specific tumor spectrum in pten knockin mice,” PNAS USA, vol. 7 No. 11, 2010, pp. 5142-5147.
[cited by applicant]
Wang, et al., “Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment,” Cancer Cell, vol. 32, No. 1, 2017, pp. 42-56.
[cited by applicant]
Wolman, et al., “A genome-wide screen identifies PAPP-AA-mediated IGFR signaling as a novel regulator of habituation learning,” Neuron, vol. 82, No. 6, 2015, pp. 1200-1211.
[cited by applicant]
Yang, et al., “Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells,” J. Med. Chem., vol. 50, No. 26, 2007, pp. 6458-646…
[cited by applicant]
Ye and Tu, “Sink into the Epigenome: Histones as Repositories That Influence Cellular Metabolism,” Trends Endocrinol Metab., vol. 29, No. 9, 2018, 262-237.
[cited by applicant]
Zabka, et al., “Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase,” Toxicol. Sci., vol. 144, No. 1, 2015, pp. 163-172.
[cited by applicant]
Zamporlini, et al., “Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD(+) biosynthetic machinery in mammalian cells,” FEBS J. Vol. 281, No. 22, 201…
[cited by applicant]
Zhao, et al., “Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration,” Mol. Cancer Ther., vol. 16, No. 12, 2017, pp. 2677-26…
[cited by applicant]
Zhou, et al., “Tyrosyl-DNA phosphodiesterase and the repair of 3′-phosphoglycolate-terminated DNA double-strand breaks,” DNA Repair, vol. 8, No. 8, 2009, pp. 901-911.
[cited by applicant]